37 results
ARS
2024 FY
ABSI
Absci Corp
23 Apr 24
Annual report to shareholders
4:10pm
.......................................................................................................................... 78 Item 4. Mine Safety Disclosures … better safety profiles in patients. Hence, building large training data sets for biologic drugs interactions offers the potential for AI models
8-K
EX-1.1
ABSI
Absci Corp
28 Feb 24
Absci Announces Proposed Public Offering of Common Stock
4:06pm
to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants … , distribution, storage, marketing, advertising, promotion, sale, export, import, use, handling, safety, efficacy, or manufacturing of pharmaceutical
424B5
ABSI
Absci Corp
28 Feb 24
Prospectus supplement for primary offering
8:34am
identity, safety, strength, quality, and purity. The FDA may convene an advisory committee, typically a panel that includes clinicians and other … experts, to provide clinical insight on applications which present difficult questions of safety or efficacy and to review, evaluate and recommend whether
8-K
3nauys wzh9lzgdna17w
27 Feb 24
Results of Operations and Financial Condition
4:45pm
424B5
mug6ahz sp1gyk2
27 Feb 24
Prospectus supplement for primary offering
4:40pm
8-K
EX-1.1
4hqbtoue7l7sjykial
16 Jun 23
Entry into a Material Definitive Agreement
4:23pm
ARS
z6drlzsoek1hd
28 Apr 23
Annual report to shareholders
12:00am
8-K
EX-3.1
qc7cjei3xaj5r
16 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:07pm
DEF 14A
u48giju
26 Apr 22
Definitive proxy
4:39pm
10-K
sh4899
22 Mar 22
Annual report
5:20pm